News Jazz orchestrates a $4bn cancer alliance with AbCellera Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.
News Poolbeg expects first data for CRS drug in the summer A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.
News Lilly trumpets strong result for Jaypirca in CLL at EHA New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.
News Data could move J&J's Talvey earlier in myeloma therapy Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.
News AZ's Truqap and Roche assay cleared for PTEN prostate cancer AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.
News Pushy NHS chatbots 'can put patients off screening' Amid the push to digitise the UK health service, a study has sounded a note of caution about entrusting important patient appointments to chatbots.
News Roivant wins FDA approval for first targeted dermatomyositis... Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
